AbbVie (prior sponsor, Abbott)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AbbVie (prior sponsor, Abbott) sits in the top decile of US sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count).
AbbVie (prior sponsor, Abbott): 88 sponsored US clinical trials, none currently recruiting.
AbbVie (prior sponsor, Abbott) sponsors 88 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 83 completed. 17 of these trials are in Phase 3-4 (later-stage) and 70 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupron, with 1 trials.
Top-decile sponsor footprint
AbbVie (prior sponsor, Abbott) ranks in the top decile of sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
83 of 88 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
88 total, page 1 of 2
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab
NCT01752855
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
NCT01741493
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
NCT01686555
A Study of ABT-414 in Subjects With Solid Tumors
NCT01741727
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee
NCT01668511
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
NCT01690195
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01678755
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
NCT01676935
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
NCT01557777
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
NCT01589419
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
NCT01712178
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01655680
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
NCT01579279
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
NCT01549834
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
NCT01527916
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
NCT01563536
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
NCT01741142
A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee
NCT01444365
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
NCT01464827
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
NCT01406119
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
NCT01399580
An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females
NCT01403038
Phase 2 Chronic Low Back Pain Study
NCT01364922
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
NCT01356849
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain
NCT01345045
Acute Pain Study Following Bunionectomy
NCT01333722
Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
NCT01314261
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT01306617
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
NCT01255657
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
NCT01185301
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
NCT01221298
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
NCT01185288
A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee
NCT01207115
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
NCT01134315
The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients
NCT01163617
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
NCT01110473
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
NCT01113957
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
NCT01077700
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
NCT01095562
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
NCT01123876
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
NCT01110486
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
NCT01074008
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00660387
Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy
NCT01038609
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00868413
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
NCT00948909
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
NCT01009073
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
NCT00878449
Study of Adalimumab in Patients With Axial Spondyloarthritis
NCT00939003
Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction
NCT00935311
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 51 |
| Phase 3 | 16 |
| Phase 4 | 1 |
How the AbbVie (prior sponsor, Abbott) early-phase archive is shaped
88 indexed studies, none listed as recruiting (0% open); 83 completed (94%).
Phase mix: 17 late (III/IV) vs 70 early (I/II) (early-phase heavy).
Top condition: Lupron (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AbbVie (prior sponsor, Abbott): archived-pipeline peers nationwide
Peers matched on 88 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AbbVie (prior sponsor, Abbott) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 88 archived trials
- Pacira Pharmaceuticals · 88 trials · 6% recruiting
- University of Medicine and Dentistry of New Jersey · 88 trials · 0% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
- Florida International University · 89 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this AbbVie (prior sponsor, Abbott) page
88 registered trials is a research-attention snapshot, not an endorsement of AbbVie (prior sponsor, Abbott) or any single study.
- None of AbbVie (prior sponsor, Abbott)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lupron is the condition AbbVie (prior sponsor, Abbott) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupron trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AbbVie (prior sponsor, Abbott) pipeline card: 88 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.